We report here that a high GP88 expression of 3+ represents a threshold that can stratify ER+ breast cancer patients in a high risk group associated with an increased probability of recurrence and mortality when compared to patients with a lower GP88 expression (GP88 < 3+). This evidence concerns the gene ESR1 and breast carcinoma.